Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug
response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic …

Introduction: The consequences of chronic disease are vast and unremitting; hence,
understanding the pathogenic mechanisms mediating such disorders holds promise to …

SI–B001 is a new EGFR/HER3 bi-specific antibody showing encouraging anti-tumor efficacy
in the preclinical studies and was ready for further clinical research. To help with the dose …

Despite continuous efforts to improve the process of drug discovery and development,
achieving success at the clinical stage remains challenging because of a persistent …

Advancements in imaging techniques have led to a rapid growth of available imaging data.
Interpretation of the imaging data and extraction of biologically, physiologically and/or …

The epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors (TKIs)
monotherapies have limited efficacy in the treatment of EGFR mutation-negative non-small …

Biomarkers are mostly correlated to a complex biomedical process, such as disease
propagation or drug action, which is affected by a multitude of biological mechanisms …

Objectives: Clinical trial simulations are usually conducted at later stages of drug
development typically requiring clinical data from Phase I/II/IIb. Our objective is to establish a …